(XBI) S&P Biotech - Overview
ETF Category: Health | Exchange: NYSE ARCA (USA) | Market Cap: 8.324m USD | Total Return: 78% in 12m
TER: 0.35%
Avg Turnover: 1.27B USD
Peers RS (IBD): 95.8
Warnings
No concerns identified
Tailwinds
No distinct edge detected
The SPDR® S&P Biotech ETF (XBI) aims to replicate the S&P Biotechnology Select Industry Index by using a sampling approach, allocating at least 80% of its assets to the index’s constituents, which represent the biotech segment of the broader S&P Total Market Index.
As of the latest data, XBI carries a low expense ratio of 0.35%, manages roughly $2.1 billion in assets, and posted a year-to-date return of about 12% driven by strong FDA approval pipelines and robust R&D spending in the sector. Recent macro trends, such as easing interest rates and heightened investor appetite for innovative therapeutics, continue to bolster biotech valuations.
For deeper insights, you might explore ValueRay’s analytical tools to complement your research.
- Biotech innovation drives new drug approvals and revenue growth
- Clinical trial failures increase development costs and risk
- Regulatory changes impact drug pricing and market access
- Healthcare spending trends influence demand for biotech products
- Interest rates affect biotech company valuations and funding
Over the past week, the price has changed by +5.33%, over one month by +9.53%, over three months by +7.02% and over the past year by +77.97%.
| Analysts Target Price | - | - |